363 related articles for article (PubMed ID: 10533795)
1. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
Lirussi F; Beccarello A; Bortolato L; Morselli-Labate AM; Crovatto M; Ceselli S; Santini G; Crepaldi G
Liver; 1999 Oct; 19(5):381-8. PubMed ID: 10533795
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
[TBL] [Abstract][Full Text] [Related]
3. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
[TBL] [Abstract][Full Text] [Related]
4. Improvement of alanine aminotransferase by administration of suplatast tosilate plus ursodeoxycholic acid in patients with resistance to ursodeoxycholic acid monotherapy on hepatitis C virus-related chronic liver disease.
Matsuda Y; Inada M; Maeda H; Matsuyama T
Intern Med; 2002 Oct; 41(10):774-9. PubMed ID: 12412994
[TBL] [Abstract][Full Text] [Related]
5. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
6. Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
Boucher E; Guyader D; Jacquelinet S; Andre P; Mendler MH; Turlin B; Canva V; Nousbaum JB; Bernard PH; Nouel O; Raabe JJ; Dao T; Gasser P; Verger P; Boutin J; Bergerault P; Joram F; Colmar P; Messner M; Brissot P; Deugnier Y
Dig Liver Dis; 2000; 32(1):29-33. PubMed ID: 10975752
[TBL] [Abstract][Full Text] [Related]
7. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.
Tsubota A; Kumada H; Arase Y; Chayama K; Saitoh S; Ikeda K; Kobayashi M; Suzuki Y; Murashima N
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1077-83. PubMed ID: 10524635
[TBL] [Abstract][Full Text] [Related]
8. Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C.
Vandelli C; Renzo F; Braun HB; Tisminetzky S; Albrecht M; De Palma M; Ranzi A; Di Marco G; Stroffolini T; Baralle F; Ventura E; Michel G
J Med Virol; 1999 May; 58(1):26-34. PubMed ID: 10223542
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial.
Tanaka K; Kondo M; Sakaguchi T; Saito S; Arata S; Ikeda M; Kitamura T; Morimoto M; Sekihara H
J Gastroenterol Hepatol; 1996 Dec; 11(12):1155-60. PubMed ID: 9034935
[TBL] [Abstract][Full Text] [Related]
10. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
[TBL] [Abstract][Full Text] [Related]
11. Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients.
Komatsu F; Takasaki K
Liver; 1999 Oct; 19(5):375-80. PubMed ID: 10533794
[TBL] [Abstract][Full Text] [Related]
12. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.
Fabris P; Tositti G; Mazzella G; Zanetti AR; Nicolin R; Pellizzer G; Benedetti P; de Lalla F
Aliment Pharmacol Ther; 1999 Sep; 13(9):1187-93. PubMed ID: 10468700
[TBL] [Abstract][Full Text] [Related]
13. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C.
Lu CL; Chan CY; Hwang SJ; Lu RH; Lee SD
J Gastroenterol Hepatol; 1995; 10(4):432-7. PubMed ID: 8527710
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.
Poupon RE; Bonnand AM; Queneau PE; Trépo C; Zarski JPí ; Vetter D; Raabe JJ; Thieffin G; Larrey D; Grangé JD; Capron JP; Serfaty L; Chrétien Y; St Marc Girardin MF; Mathiex-Fortunet H; Zafrani ES; Guéchot J; Beuers U; Paumgartner G; Poupon R
Scand J Gastroenterol; 2000 Jun; 35(6):642-9. PubMed ID: 10912666
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
[TBL] [Abstract][Full Text] [Related]
17. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C.
Reedy DW; Loo AT; Levine RA
Dig Dis Sci; 1998 Sep; 43(9):2156-9. PubMed ID: 9753286
[TBL] [Abstract][Full Text] [Related]
18. Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients.
Shahid M; Idrees M; Nasir B; Raja AJ; Raza SM; Amin I; Rasul A; Tayyab GU
Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):788-94. PubMed ID: 24781355
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.
Abdelmalek MF; Harrison ME; Gross JB; Poterucha JJ; Gossard AA; Spivey JR; Rakela J; Lindor KD
J Clin Gastroenterol; 1998 Mar; 26(2):130-4. PubMed ID: 9563925
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
